125827-86-3

Basic information

• Product Name: 1-(3-fluorophenyl)cyclohexylamine
• Synonyms: 1-(3-fluorophenyl)cyclohexylamine;1-(3-Fluorophenyl)cyclohexanamine;Cyclohexanamine,1-(3-fluorophenyl)-;1-(3-fluorophenyl)cyclohexan-1-amine
• CAS NO: 125827-86-3
• Molecular Formula: C₁₂H₁₆FN
• Molecular Weight: 193.2605
• Mol File: 125827-86-3.mol

Chemical Properties

• Boiling Point: 277.8°Cat760mmHg
• Flash Point: 132.9°C
• Appearance: /
• Density: 1.068g/cm³
• Vapor Pressure: 0.00443mmHg at 25°C
• Refractive Index: 1.526
• PKA: 9.09±0.70(Predicted)
• CAS DataBase Reference: 1-(3-fluorophenyl)cyclohexylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-fluorophenyl)cyclohexylamine(125827-86-3)
• EPA Substance Registry System: 1-(3-fluorophenyl)cyclohexylamine(125827-86-3)

Safety Data

• Hazardous Substances Data: 125827-86-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
1-(3-fluorophenyl)cyclohexylamine is used as a compound in medicinal chemistry for its capacity to interact with biological receptors and enzymes, which may contribute to the development of new drugs.
Used in Drug Development:
In drug development, 1-(3-fluorophenyl)cyclohexylamine is utilized as a potential candidate for creating pharmaceuticals, given its ability to engage with biological targets that could be relevant to treating various diseases.
Used in Organic Synthesis:
1-(3-fluorophenyl)cyclohexylamine is used as a building block in the synthesis of other organic compounds, playing a role in the creation of more complex molecules for various applications in chemistry and related fields.
Used in Research:
In research settings, 1-(3-fluorophenyl)cyclohexylamine is employed to study its properties and explore its potential uses, advancing the understanding of its role in chemical and biological systems.

InChI:InChI=1/C12H16FN/c13-11-6-4-5-10(9-11)12(14)7-2-1-3-8-12/h4-6,9H,1-3,7-8,14H2

Upstream product

• 1496-35-1 1-(3-fluorophenyl)cyclohexanol 
• 214262-91-6 1-(3-fluorophenyl)cyclohexanecarbonitrile 
• 111-24-0 1,5-dibromo-pentane 
• 501-00-8 3-fluorophenylacetonitrile 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 
• 108-94-1 cyclohexanone 

Downstream Products

• 1375466-18-4 2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide 

Relevant articles and documents

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA

Disclosed are histone deacetylase (HDAC) inhibitors, or combinations comprising an HDAC inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic lymphocytic leukemia in a subject in need thereof. Also provided herein are methods for treating chronic lymphocytic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor. Other related methods are disclosed.

METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS

The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.

TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS

Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.

PYRIMIDINE HYDROXY AMIDE COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY

The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering to the subject a th

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND BENDAMUSTINE FOR USE IN THE TREATMENT OF LYMPHOMA

The invention relates to pharmaceutical combinations comprising an HDAC inhibitor and bendamustine; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions for treating lymphoma in a subject in need thereof.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS

The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatrent of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.

HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.

HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues

Thirty-eight analogues of 1-phenylcyclohexylamine (PCA), a phencyclidine (PCP) derivative, were examined for their activities in the mouse maximal electroshock (MES) seizure test and in a motor-toxicity assay.In addition, we determined the binding affinities of the compounds for PCP acceptor sites in rat brain membranes labeled with -1-piperidine.Many of the analogues were protective against MES seizures (ED50s of 4-41 mg/kg, ip) and all of these compounds caused motor toxicity.The potencies in the motor toxicity and MES seizure tests showed a moderate correlation with the affinities for PCP sites.Several analogues exhibited a greater separation of potencies in the motor toxicity and MES seizure tests than did the parent compound PCA.These were obtained by (i) 3-methylation of the cyclohexyl ring trans to the phenyl ring, (ii) methoxylation at the ortho position on the phenyl ring, and (iii) contraction of the cyclohexane ring to form the corresponding cyclopentane.